TY - JOUR
T1 - One-year outcome after percutaneous coronary intervention for acute coronary syndrome ― An analysis of 20,042 patients from a Japanese nationwide registry
AU - Sawano, Mitsuaki
AU - Kohsaka, Shun
AU - Ishii, Hideki
AU - Numasawa, Yohei
AU - Yamaji, Kyohei
AU - Inohara, Taku
AU - Amano, Tetsuya
AU - Ikari, Yuji
AU - Nakamura, Masato
N1 - Funding Information:
M.S. received a Japan Promotional Society for Cardiovascular Disease Sakakibara Memorial Research Grant, a grant from the Japan Heart Foundation, and a JSPS KAKENHI Grant Number JP18K17332 during the conduct of the study, as well as grants from Takeda Pharma and Takeda Japan Medical Office Funded Research Grant 2018 not relevant to this study. S.K. has received investigator-initiated grant funding from Bayer and Daiichi Sankyo and personal consulting fees from Bayer and Bristol-Myers Squibb. H.I. has received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, Otsuka Pharma, Pfizer, Mochida Pharma, MSD, and JSPS KAKENHI Grant Number JP21K08064. T.A. has received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. T.I. has received a research grant from Boston Scientific. M.N. has received remuneration for lectures from Daiichi Sankyo, Sanofi, Bayer, Nippon Boehringer Ingelheim, Bristol-Myers Squibb, Terumo, Japan Lifeline, Abbott, Boston Scientific, Medtronic, and Nipro, and investigator-initiated grant funding from Sanofi and Daiichi Sankyo. H.I., T.A., and Y.I. are members of Circulation Journal’s Editorial Team. The remaining authors have no conflicts of interest to report.
Funding Information:
This work was supported by the Japanese Association of Cardiovascular Intervention and Therapeutics, the Japan Agency for Medical Research and Developments (Grant no. 17ek0210097h0001), and by the JSPS KAKENHI Grant Number JP18K17332. There are no relationships with industry.
Publisher Copyright:
© 2021 Japanese Circulation Society. All rights reserved.
PY - 2021/9/24
Y1 - 2021/9/24
N2 - Background: Acute coronary syndrome (ACS) hospital survivors experience a wide array of late adverse cardiac events, despite considerable advances in the quality of care. We investigated 30-day and 1-year outcomes of ACS hospital survivors using a Japanese nationwide cohort. Methods and Results: We studied 20,042 ACS patients who underwent percutaneous coronary intervention (PCI) in 2017: 10,242 (51%) with ST-elevation myocardial infarction (STEMI), 3,027 (15%) with non-ST-elevation myocardial infarction (NSTEMI), and 6,773 (34%) with unstable angina (UA). The mean (±SD) age was 69.6±12.4 years, 77% of the patients were men, and 20% had a previous history of PCI. The overall 30-day all-cause, cardiac, and non-cardiac mortality rates were 3.0%, 2.4%, and 0.6%, respectively. The overall 1-year incidence of all-cause, cardiac, and non-cardiac death was 7.1%, 4.2%, and 2.8%, respectively. Compared with UA patients, STEMI patients had a higher risk of all fatal events, non-fatal ischemic stroke, and acute heart failure, and NSTEMI patients had a higher risk of heart failure. Conclusions: The results from our ACS hospital survivor PCI database suggest the need to improve care for the acute myocardial infarction population to lessen the burden of 30-day mortality due to ACS, heart failure, and sudden cardiac death, as well as 1-year ischemic stroke and heart failure events.
AB - Background: Acute coronary syndrome (ACS) hospital survivors experience a wide array of late adverse cardiac events, despite considerable advances in the quality of care. We investigated 30-day and 1-year outcomes of ACS hospital survivors using a Japanese nationwide cohort. Methods and Results: We studied 20,042 ACS patients who underwent percutaneous coronary intervention (PCI) in 2017: 10,242 (51%) with ST-elevation myocardial infarction (STEMI), 3,027 (15%) with non-ST-elevation myocardial infarction (NSTEMI), and 6,773 (34%) with unstable angina (UA). The mean (±SD) age was 69.6±12.4 years, 77% of the patients were men, and 20% had a previous history of PCI. The overall 30-day all-cause, cardiac, and non-cardiac mortality rates were 3.0%, 2.4%, and 0.6%, respectively. The overall 1-year incidence of all-cause, cardiac, and non-cardiac death was 7.1%, 4.2%, and 2.8%, respectively. Compared with UA patients, STEMI patients had a higher risk of all fatal events, non-fatal ischemic stroke, and acute heart failure, and NSTEMI patients had a higher risk of heart failure. Conclusions: The results from our ACS hospital survivor PCI database suggest the need to improve care for the acute myocardial infarction population to lessen the burden of 30-day mortality due to ACS, heart failure, and sudden cardiac death, as well as 1-year ischemic stroke and heart failure events.
KW - Acute coronary syndrome
KW - Acute myocardial infarction
KW - Mortality
KW - Outcome
KW - Percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85115411803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115411803&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-21-0098
DO - 10.1253/circj.CJ-21-0098
M3 - Article
C2 - 34162778
AN - SCOPUS:85115411803
SN - 1346-9843
VL - 85
SP - 1756
EP - 1767
JO - Circulation Journal
JF - Circulation Journal
IS - 10
ER -